ArticleBMC biotechnology2025
Evaluating the anticancer efficacy of Chara vulgaris ethanolic extract and selenium nanoformulation in Ehrlich carcinoma mice: role of autophagy and apoptosis.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Article
- Article
- Harnessing Nature for Breast Cancer Management: Effects of Fisetin-Loaded Nigellasomes Embedded in Microneedles Improve Tumor Suppression and Reduce Oxidative Stress.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBioactive compounds with a wide range of chemical compositions and biological functions are found in the Chlorophyceae family. The present work investigated the anticancer effect of ethanolic extract from Chara vulgaris (C. vulgaris) and its selenium nanoformulation (CvSeNPs) against solid Ehrlich carcinoma (SEC).
methodsGas chromatography-mass spectroscopy was used to analyze C. vulgaris, and many analytical methods were used to characterize the biosynthesized CvSeNPs, including zeta potential, particle size, polydispersity index (PDI), SEM, TEM, and FTIR. In addition, mice with SEC were randomly assigned to seven equal groups (n = 6) to investigate possible mechanisms behind the antitumor activity. Group 1: Tumor control, group 2: Tamoxifen (10 mg/kg), group 3: Free SeNPs, group 4: C. vulgaris (25 mg/kg), group 5: C. vulgaris (50 mg/kg), group 6: 25 mg/kg CvSeNPs, group 7: 50 mg/kg CvSeNPs.
resultsGas chromatography-mass spectroscopy analysis of the ethanolic extract of C. vulgaris revealed the presence of several bioactive chemicals that may promote anticancer activity. Protein levels of TNF-α, NF-кB, VEGF, and Bcl-2 were suppressed in the CvSeNPs group (50 mg/kg), whereas those of caspase-3, BAX, P53, P62, LC3, and Beclin1 were increased. Additionally, CvSeNPs significantly exceeded similar dosages of free extract in terms of caspase-3, BAX, Bcl-2, P53, TNF-α, NF-кB, VEGF, P62, LC3, and Beclin1 gene expression.
conclusionThe CvSeNPs mediated their positive anticancer impact, which manifested as a decrease in tumor volume and an improvement in overall survival rate, by promoting autophagy, apoptosis, and lowering inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.